New 24-Valent vaccine aims to shield children from more pneumonia strains
NCT ID NCT07300644
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new vaccine called PCV24 in 420 healthy children aged 2 months to 5 years. The vaccine targets 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. Researchers will compare it to an existing vaccine to see if it is safe and triggers a strong immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
24-valent pneumococcal conjugate vaccine (PCV24)
What this could lead to
If successful, this vaccine could protect children against 24 types of pneumococcal bacteria, potentially preventing more infections than current vaccines.
What could go wrong
This is an early phase 2 trial with only 420 children, so results may not apply to all kids. The vaccine may not work as well as expected or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qichun District Center for Disease Prevention and Control
RECRUITINGHuanggang, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xian'an District Center for Disease Prevention and Control
RECRUITINGXianning, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangzhou District Center for Disease Prevention and Control
RECRUITINGXiangyang, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••